
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana is a strong performer in the private health insurance space, with a focus on lucrative government-sponsored programs. Their aggressive growth strategy for the individual Medicare Advantage plans is paying off, with estimated 25% year-over-year growth and steady enrollment. Despite potential challenges like mortality and legislative risks, Humana's results have been impressive thus far, with strong quarterly earnings, efficient cost management, and a promising outlook for the future. Overall, Humana presents a favorable investment opportunity in the healthcare sector with potential for steady revenue growth and reasonable valuation.
Bears say
Humana is heavily reliant on its government-sponsored programs, which comprise nearly all of its medical membership and are subject to potential margin contraction. Despite some margin expansion potential in CY27 and CY28, the company may struggle to achieve its target margin of 3.0%, which casts doubt on its future earnings potential and justifies a negative outlook.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares